vcvibes

Borealis Ventures

SEC exempt reporting adviser (venture capital exemption).

HQ
NH

Borealis Ventures partners closely with exceptional entrepreneurs to build market-defining companies focused on transforming healthcare through new therapies, digital innovation, and other technologies. Its team includes partners Phil Ferneau, Ben Shaw, and Julia Stephanus, along with a principal, venture fellows, and a venture consultant. Portfolio companies named in the facts include Triveni Bio, Astra Therapeutics, Ankyra Therapeutics, and Compass Therapeutics.

New fund likely raising soon

The firm's newest fund is 4 to 7 years past its first sale and no newer Form D has been filed.

01 · Says / Does

TagSaysDoes
StagesNot statedNot enough dated deals
SectorsHealthtech, Digital health, BiotechNot enough dated deals
RegionsUS, GlobalNot enough dated deals

Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.

02 · Fund history

FundYearSizeStatus
Borealis Fund VI, LP

Borealis Ventures partners closely with exceptional entrepreneurs to build market-defining companies. It focuses on transforming healthcare through new therapies, digital innovation, and other technologies, investing at the earliest stages as lifecycle investors across life science platforms, digital health, and animal health. Inferred from the firm's website

2022$5.29M to $100M (Form D)Late investment period
Borealis Fund V - Veterinary Innovation, LP2021$33.59M to $50M (Form D)Follow-ons only

03 · People across funds

04 · Recent deals

No dated deals found yet.

05 · Latest from the firm

No news from the firm's website yet.

06 · Sources

  1. https://www.borealis.vc/
  2. https://www.borealis.vc/team
  3. https://www.borealis.vc/news
  4. https://www.borealis.vc/about

Fund dates and sizes are from SEC Form D filings.

Last verified: Oct 28, 2026